Latest News on BBNX

Financial News Based On Company


Advertisement
Advertisement

Beta Bionics CCO Mark Hopman sells $12,570 in company stock

https://www.investing.com/news/insider-trading-news/beta-bionics-cco-mark-hopman-sells-12570-in-company-stock-93CH-5038381
Beta Bionics CCO Mark Hopman sold 775 shares of company common stock for $12,570 on November 16, 2026, as part of a Rule 10b5-1 trading plan. On the same day, he acquired 775 shares by exercising employee stock options for $3,952. Following these transactions, Mr. Hopman directly owns 54,143 shares and holds options for an additional 20,950 shares of Beta Bionics.

Mark Hopman exercised options at $5.10 and sold 775 Beta Bionics (BBNX) shares the same day.

https://www.stocktitan.net/sec-filings/BBNX/form-4-beta-bionics-inc-insider-trading-activity-04a4732c0753.html
Mark Hopman, Chief Commercial Officer of Beta Bionics (BBNX), exercised options for 775 shares at $5.10 per share on November 16, 2026. The same day, he sold these 775 shares at $16.22 per share under a prearranged Rule 10b5-1 plan, resulting in an approximate pre-tax spread of $9,000. After these transactions, his reported option holdings were 20,950 shares.

Senseonics, Beta Bionics integrate diabetes technology

https://www.medtechdive.com/news/senseonics-beta-bionics-integrate-diabetes-technology/875120/
Diabetes technology companies Senseonics and Beta Bionics have integrated their glucose sensors and insulin pumps, making Senseonics' Eversense 365 continuous glucose monitor compatible with Beta Bionics' iLet Bionic Pancreas. This collaboration aims to simplify diabetes management and expand device choices for patients. The companies also plan to integrate Senseonics’ one-year CGM with Beta Bionics’ new Mint tubeless patch pump in the future.

Form 144 BETA BIONICS For: 15 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-beta-bionics-for-15-november-93CH-4959063
This article from Investing.com announces the filing of Form 144 for BETA BIONICS, dated November 15, 2026. Form 144 is a notice of the intent to sell restricted securities. The brief article provides no further details beyond the announcement of the filing and the date.

Form 144 Beta Bionics For: 13 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-beta-bionics-for-13-november-93CH-4956379
This article from Investing.com is a brief notice about a Form 144 filing for Beta Bionics on November 13. Form 144 is a notice of the intent to sell restricted securities. The article provides minimal information beyond the filing date and company name.
Advertisement

Beta Bionics CFO Stephen Feider sells $12,648 in company stock By Investing.com

https://uk.investing.com/news/stock-market-news/beta-bionics-cfo-stephen-feider-sells-12648-in-company-stock-93CH-4979031
Beta Bionics CFO Stephen Feider sold 744 shares of the company's common stock for $12,648 on November 9, 2026, as part of a Rule 10b5-1 trading plan. On the same day, he acquired 744 shares by exercising employee stock options for $3,794. The company recently reported record third-quarter revenue but missed earnings expectations, while analysts have maintained varied ratings and price targets.

Beta Bionics (BBNX) CFO exercised 744 options at $5.10, then sold 744 shares under a trading plan.

https://www.stocktitan.net/sec-filings/BBNX/form-4-beta-bionics-inc-insider-trading-activity-d6150833d81e.html
Beta Bionics (BBNX) Chief Financial Officer Stephen Feider exercised 744 stock options at $5.10 per share on November 9, 2026, and subsequently sold 744 common shares at a weighted average price of $17.001344 per share. This transaction, which resulted in an approximate pre-tax spread of $9,000, was conducted under a Rule 10b5-1 trading plan adopted on July 31, 2026. After the exercise, his reported option position was 38,569.

These healthcare stocks have tumbled in 2026, yet Quant ratings stay positive

https://www.tradingview.com/news/seekingalpha:0e7d01cd4094b:0-these-healthcare-stocks-have-tumbled-in-2026-yet-quant-ratings-stay-positive/
Several healthcare stocks have experienced significant declines in 2026, with some falling over 40%, despite maintaining Buy or Strong Buy Quant Ratings from Seeking Alpha. The sector faces challenges from regulatory uncertainty and high financing costs, but innovation and demand for advanced treatments offer growth opportunities. The article highlights 10 underperforming healthcare stocks that still hold favorable quantitative assessments.

Form 144 Beta Bionics For: 10 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-beta-bionics-for-10-november-93CH-4945166
This article from Investing.com reports on the Form 144 filing for Beta Bionics, specifically for November 10th. The filing is related to the company BBNX. The content is very brief, mainly serving as a notice for the filing.

Beta Bionics CFO Stephen Feider sells $6,507 in company stock By Investing.com

https://ca.investing.com/news/stock-market-news/beta-bionics-cfo-stephen-feider-sells-6507-in-company-stock-93CH-4945379
Beta Bionics CFO Stephen Feider sold 382 shares of company stock worth $6,507 on November 5, 2026, as part of a Rule 10b5-1 trading plan. On the same day, he acquired 382 shares through an employee stock option exercise for $1,948. The company recently reported a record third-quarter revenue of $35.5 million and raised its full-year 2026 revenue guidance, despite an adjusted EPS miss.
Advertisement

Form 4 Beta Bionics Inc: Stephen Feider (CFO) For: 5 November

https://uk.investing.com/news/stock-market-news/form-4-beta-bionics-inc-stephen-feider-cfo-for-5-november-93CH-4970475
This article reports on a Form 4 filing for Beta Bionics Inc, specifically concerning Stephen Feider, the CFO, for transactions made on November 5th. It is a brief announcement from Investing.com, typical for insider trading disclosures. The article also includes various market data and other news unrelated to the main subject.

Form 144 Beta Bionics For: 10 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-beta-bionics-for-10-november-93CH-2795742
This article from Investing.com announces the filing of Form 144 for Beta Bionics on November 10th. It is a brief, one-sentence news item focused on a specific regulatory filing for the company. The content primarily consists of navigation and market data, with the core news being the Form 144 filing.

After exercising $5.10 options, Beta Bionics (BBNX) CFO sells 382 shares under a trading plan.

https://www.stocktitan.net/sec-filings/BBNX/form-4-beta-bionics-inc-insider-trading-activity-1a35e5d71e33.html
Beta Bionics (BBNX) CFO Stephen Feider exercised 382 employee stock options at $5.10 per share and simultaneously sold 382 common shares at a weighted average price of $17.036649 per share on November 5, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted on July 31, 2026. After the exercise and sale, Feider directly held 39,313 options and 159,378 common shares.

Form 144 Beta Bionics, Inc. Filed by: Feider Stephen

https://www.streetinsider.com/SEC+Filings/Form+144+Beta+Bionics%2C+Inc.+Filed+by%3A+Feider+Stephen/27316068.html
Stephen Feider, an officer of Beta Bionics, Inc., has filed a Form 144 Notice of Proposed Sale of Securities, indicating his intention to sell 744 shares of common stock. The securities were acquired through stock options on November 9, 2026, and the sale is expected to occur on the same day on NASDAQ. The filing also details previous sales by Feider in the past three months, including 382 shares on November 5, 2026, and 6,675 shares on September 2, 2026.

Form 4 Beta Bionics, Inc. For: Nov 05 Filed by: Feider Stephen

https://www.streetinsider.com/SEC+Filings/Form+4+Beta+Bionics%2C+Inc.+For%3A+Nov+05+Filed+by%3A+Feider+Stephen/27315571.html
Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), filed a Form 4 report detailing transactions on November 5, 2026. The report shows that Feider acquired 382 shares of common stock at $5.1 per share through an option exercise and subsequently sold the same number of shares at a weighted average price of $17.0366 pursuant to a Rule 10b5-1 Plan. Following these transactions, Feider beneficially owns 159,378 shares of common stock and 39,313 employee stock options.
Advertisement

At $16.90 a share, Beta Bionics (BBNX) executive Mark Hopman sells 370 shares under a trading plan.

https://www.stocktitan.net/sec-filings/BBNX/form-4-beta-bionics-inc-insider-trading-activity-1e00df2b9bce.html
Mark Hopman, Chief Commercial Officer at Beta Bionics, Inc. (BBNX), sold 370 shares of common stock at $16.90 per share on November 2, 2026. This transaction was conducted under a Rule 10b5-1 plan established on June 10, 2026. Following the sale, Hopman directly holds 54,143 shares of the company.

Beta Bionics Announces Participation at Upcoming Investor Conferences

https://www.manilatimes.net/2026/11/03/tmt-newswire/globenewswire/beta-bionics-announces-participation-at-upcoming-investor-conferences/2460553/amp
Beta Bionics, Inc. (Nasdaq: BBNX) has announced its participation in several upcoming investor conferences in November and December 2026. Management will present at the Wolfe Research 8th Annual Healthcare Conference, the Stifel 2026 Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference, as well as host in-person meetings at the Jefferies 2026 Global Healthcare Conference. The company, a leader in advanced diabetes management solutions, will webcast its presentations live on its investor relations website.

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026

https://www.eagletribune.com/region/class-action-deadline-tonight-faruqi-faruqi-llp-reminds-beta-bionics-nasdaq-bbnx-investors-of-securities/article_9aeca818-b6e9-5a32-bcfa-7518b84ff64a.html
Faruqi & Faruqi, LLP is investigating potential securities fraud claims against Beta Bionics, Inc. (NASDAQ: BBNX) and reminds investors that the deadline to seek the role of lead plaintiff in a federal securities class action lawsuit is November 3, 2026. The lawsuit alleges that Beta Bionics made false and misleading statements regarding the safety and efficacy of its iLet Bionic Pancreas insulin pump and downplayed critical FDA findings concerning its quality management system and unreported serious injuries. Investors who purchased BBNX securities during the alleged Class Period may be eligible to participate.

Beta Bionics, Inc. (NASDAQ:BBNX) SHAREHOLDER ALERT:

https://www.globenewswire.com/news-release/2026/11/03/3394319/0/en/beta-bionics-inc-nasdaq-bbnx-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-beta-bionics-inc-securities-lawsuit-contact-portnoy-law-firm.html
The Portnoy Law Firm has filed a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made false and misleading statements regarding issues with its iLet Bionic Pancreas insulin pump, including serious malfunctions and dangerously high insulin dosing. Investors who suffered losses have until November 3, 2026, to seek appointment as lead plaintiff.

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX

https://www.financialcontent.com/article/gnwcq-2026-11-3-suewallst-reminds-shareholders-of-a-lead-plaintiff-deadline-of-november-3-2026-in-beta-bionics-inc-lawsuit-bbnx
SueWallSt is reminding shareholders of Beta Bionics, Inc. (BBNX) about a lead plaintiff deadline of November 3, 2026, in a securities class action lawsuit. The lawsuit alleges that Beta Bionics made false or misleading statements regarding the safety and efficacy of its iLet Bionic Pancreas, leading to a significant 72% stock price decline. Shareholders who purchased shares between July 30, 2025, and February 24, 2026, and suffered losses, may be eligible for compensation.
Advertisement

Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of

https://www.globenewswire.com/news-release/2026/11/02/3393431/3080/en/levi-korsinsky-reminds-beta-bionics-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-november-3-2026-bbnx.html
Levi & Korsinsky, LLP is reminding investors of Beta Bionics, Inc. (NASDAQ: BBNX) about a pending securities class action lawsuit against the company, its CEO Sean Saint, and CFO Stephen Feider. The lawsuit alleges that the executives certified SEC filings while a June 2025 FDA Form 483, citing over 18,000 unreported iLet complaints, was withheld from shareholders. The lead plaintiff deadline for the lawsuit is November 3, 2026.

Deadline Alert: Beta Bionics, Inc. Investors Have Until

https://www.globenewswire.com/news-release/2026/11/02/3393670/0/en/deadline-alert-beta-bionics-inc-investors-have-until-november-3-2026-to-seek-lead-plaintiff-role-in-securities-fraud-class-action-glancy-prongay-wolke-rotter-llp-reminds-investors.html
Investors in Beta Bionics, Inc. (NASDAQ: BBNX) have until November 3, 2026, to seek appointment as lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that the company made materially false and misleading statements and failed to disclose critical information regarding FDA Form 483 and safety issues related to its iLet device, including over 18,000 complaints and life-threatening hypoglycemic events. These undisclosed issues led to a significant drop in Beta Bionics' stock price after preliminary Q4 2025 financial results revealed lower-than-expected new patient starts.

Beta Bionics 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Beta Bionics, Inc. - BBNX

https://www.businesswire.com/news/home/20261030980777/en/Beta-Bionics-96-Hour-Deadline-Alert-Kahn-Swick-Foti-LLC-Reminds-Investors-With-Losses-In-Excess-Of-%24100000-of-Deadline-in-Class-Action-Lawsuit-Against-Beta-Bionics-Inc.---BBNX
Kahn Swick & Foti, LLC (KSF) is reminding investors in Beta Bionics, Inc. (BBNX) who suffered losses exceeding $100,000 of the November 3, 2026 deadline to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Beta Bionics made false and misleading statements regarding its iLet Bionic Pancreas insulin pump, which is accused of malfunctioning and delivering dangerously high insulin levels, leading to severe hypoglycemic events. KSF encourages affected investors to contact them to discuss their legal rights and potential recovery.

Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

https://www.mykxlg.com/online_features/press_releases/bronstein-gewirtz-grossman-llc-urges-beta-bionics-inc-investors-to-act-class-action-filed-alleging/article_7b0257b0-a999-55d5-9242-43dea8d71d40.html
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased securities between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made false and misleading statements and failed to disclose critical FDA findings regarding its iLet Bionic Pancreas insulin pump, including deficiencies in its quality management system and unreported serious injuries. Investors who suffered losses are encouraged to join the case, with a lead plaintiff deadline of November 3, 2026.

Price to book forward of Beta Bionics, Inc. – BOATS:BBNX

https://www.tradingview.com/symbols/BOATS-BBNX/financials-statistics-and-ratios/price-book-fwd/
This article provides the "Price to book forward" metric for Beta Bionics, Inc. (BBNX) under the BOATS exchange. It is a data point typically used in financial analysis to assess a company's valuation. The content focuses on presenting this specific financial metric.
Advertisement

BBNX DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Reminds Beta Bionics, Inc. Investors They Have Until November 3rd to Seek Lead Plaintiff Role with the Firm

https://www.daily-tribune.com/online_features/press_releases/bbnx-deadline-tuesday-bragar-eagel-squire-p-c-reminds-beta-bionics-inc-investors-they-have/article_8f5cf7aa-9e47-5177-91b2-eb8713d95ba4.html
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased common stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made misleading statements regarding its iLet Bionic Pancreas insulin pump, which reportedly had serious malfunctioning issues leading to dangerous insulin dosing and hypoglycemic events. Investors have until November 3, 2026, to apply to be appointed as lead plaintiff.

BBNX DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Reminds Beta Bionics, Inc. Investors They Have Until November 3rd to Seek Lead Plaintiff Role with the Firm

https://www.lincolnjournal.com/online_features/press_releases/bbnx-deadline-tuesday-bragar-eagel-squire-p-c-reminds-beta-bionics-inc-investors-they-have/article_0e77079c-f733-5c6b-ba8b-e8ac73483748.html
Bragar Eagel & Squire, P.C. is reminding investors of Beta Bionics, Inc. (BBNX) that they have until November 3, 2026, to seek the role of lead plaintiff in a class action lawsuit. The lawsuit alleges that Beta Bionics made false and misleading statements about its iLet Bionic Pancreas insulin pump, specifically concerning numerous serious issues and the FDA's dissatisfaction with the company's response. Investors who purchased or acquired Beta Bionics common stock between July 30, 2023, and February 28, 2024, and suffered losses, are encouraged to contact the firm.

BBNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact SueWallSt

https://www.morningstar.com/news/pr-newswire/20261029ny84084/bbnx-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-beta-bionics-inc-securities-lawsuit-contact-suewallst
SueWallSt has filed a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased shares between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics failed to disclose critical information regarding an FDA Warning Letter, which highlighted thousands of unreported iLet complaints, including many involving life-threatening hypoglycemia. The company's stock experienced a significant decline after the FDA publicly released the Warning Letter.

Beta Bionics CPO Mike Mensinger sells $58,300 in stock

https://www.investing.com/news/insider-trading-news/beta-bionics-cpo-mike-mensinger-sells-58300-in-stock-93CH-4985817
Mike Mensinger, Chief Product Officer at Beta Bionics, Inc. (NASDAQ:BBNX), sold 2,650 shares of the company’s common stock for a total of $58,300 on October 27, 2026. This transaction was part of a Rule 10b5-1 trading plan adopted in September 2025, leaving Mr. Mensinger with 174,740 shares. The sale comes amidst the company reporting record third-quarter revenue but also a larger-than-expected loss.

Form 4 Beta Bionics Inc: Mike Mensinger (Chief Product Officer) For: 27 October

https://uk.investing.com/news/stock-market-news/form-4-beta-bionics-inc-mike-mensinger-chief-product-officer-for-27-october-93CH-4943919
This article reports on a Form 4 filing for Beta Bionics Inc. pertaining to Chief Product Officer Mike Mensinger. The filing is dated October 27th, and the article was published on October 30th, 2026.
Advertisement

BBNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact SueWallSt

https://www.prnewswire.com/news-releases/bbnx-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-beta-bionics-inc-securities-lawsuit---contact-suewallst-302923556.html
SueWallSt is notifying investors in Beta Bionics, Inc. (NASDAQ: BBNX) about a securities class action lawsuit filed on behalf of shareholders who purchased securities between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics' SEC filings misrepresented the nature of an FDA Warning Letter, omitting hundreds of unreported iLet complaints, including those involving life-threatening hypoglycemia. Investors who suffered losses may seek to lead the class action, with a lead plaintiff deadline of November 3, 2026.

BBNX Investor Alert: Schall, Brown & Schwartz LLP Files

https://www.globenewswire.com/news-release/2026/10/29/3391432/0/en/bbnx-investor-alert-schall-brown-schwartz-llp-files-class-action-lawsuit-against-beta-bionics-inc-and-announces-opportunity-for-investors-to-lead-class-action-lawsuit.html
Schall, Brown & Schwartz LLP has filed a federal securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased common stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made false and misleading statements regarding its iLet Bionic Pancreas insulin pump, specifically downplaying issues found by the FDA regarding its quality management system and the seriousness of unreported device malfunctions. Investors have until November 3, 2026, to seek appointment as lead plaintiff in the lawsuit.

BBNX Investor Alert: Johnson Fistel Encourages Beta Bionics, Inc. Investors to Contact the Firm Ahead of November 3, 2026 Lead Plaintiff Deadline

https://www.morningstar.com/news/pr-newswire/20261028ph83671/bbnx-investor-alert-johnson-fistel-encourages-beta-bionics-inc-investors-to-contact-the-firm-ahead-of-november-3-2026-lead-plaintiff-deadline
Johnson Fistel, PLLP has filed a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that the company made misleading statements regarding the safety, efficacy, and commercial prospects of its iLet Bionic Pancreas, particularly concerning FDA observations and customer complaints. Investors have until November 3, 2026, to file as lead plaintiff.

BBNX Shareholder Alert: November 3, 2026 Lead Plaintiff Deadline in Beta Bionics, Inc. Securities Class Action - Contact Levi & Korsinsky

https://www.prnewswire.com/news-releases/bbnx-shareholder-alert-november-3-2026-lead-plaintiff-deadline-in-beta-bionics-inc-securities-class-action---contact-levi--korsinsky-302922577.html
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of shareholders who purchased stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that the company made misleading statements regarding an FDA Warning Letter and over 18,000 unreported iLet complaints, causing the stock to decline significantly. The lead plaintiff deadline for investors is November 3, 2026.

What's Next for Beta Bionics, Inc. Shareholders After 37% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

https://www.morningstar.com/news/pr-newswire/20261028la82398/whats-next-for-beta-bionics-inc-shareholders-after-37-stock-drop-glancy-prongay-wolke-rotter-llp-explains-securities-fraud-class-action-lead-plaintiff-deadline
Glancy Prongay Wolke & Rotter LLP announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) for investors who purchased securities between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made misleading statements and failed to disclose critical safety issues and FDA observations, leading to a 37% stock drop on January 9, 2026. Investors have until November 3, 2026, to seek a lead plaintiff role in the case.
Advertisement

Kaplan Fox Notifies Beta Bionics, Inc. (NASDAQ: BBNX) Investors of a Securities Class Action ...

https://www.pmg-ky3.com/ap/ap_news/kaplan-fox-notifies-beta-bionics-inc-nasdaq-bbnx-investors-of-a-securities-class-action/article_28bac515-e3ed-5579-a502-59b768a03e78.html
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased common stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics concealed thousands of complaints regarding its iLet Bionic Pancreas insulin pump, including reports of serious hypoglycemia caused by device malfunctions. These issues were allegedly revealed through missed patient start metrics and a subsequent FDA warning letter detailing numerous violations.

Beta Bionics, Inc. Stock 12‑Month Price Target Raised to $25.1, Implies 17% Upside

https://www.tradingview.com/news/tradingview:6e800514a21bc:0-beta-bionics-inc-stock-12-month-price-target-raised-to-25-1-implies-17-upside/
According to 14 analysts, the average price target for Beta Bionics, Inc. (BBNX) stock has increased to $25.1, suggesting a potential upside of approximately 17% from its Oct. 27 closing price. The consensus rating remains "Buy" among 15 analysts, with 11 recommending a Buy and 4 a Hold.

Beta Bionics, Inc. Stock 12‑Month Price Target Raised to $25.1, Implies 17% Upside

https://www.tradingview.com/news/tradingview:6e800514a21bc:0-beta-bionics-inc-stock-12-month-price-target-raised-to-24-89-implies-16-upside/
Beta Bionics, Inc. (BBNX) has seen its average 12-month price target raised from $24.24 to $25.1 by 14 analysts, with individual forecasts ranging from $16 to $30.4 per share. This new target suggests a potential upside of approximately 17% from the October 27 closing price. The consensus rating among 15 covering analysts remains a "Buy," with 11 buy recommendations and 4 holds.

Deadline Alert: Beta Bionics, Inc. Investors Have Until

https://www.globenewswire.com/news-release/2026/10/28/3390693/34548/en/deadline-alert-beta-bionics-inc-investors-have-until-november-3-2026-to-seek-lead-plaintiff-role-in-securities-fraud-class-action-glancy-prongay-wolke-rotter-llp-reminds-investors.html
Glancy Prongay Wolke & Rotter LLP has issued a deadline alert for investors in Beta Bionics, Inc., reminding them that they have until November 3, 2026, to seek a lead plaintiff role in a securities fraud class action lawsuit. The lawsuit covers investors who purchased Beta Bionics securities between July 30, 2025, and February 24, 2026, alleging the company failed to disclose material adverse facts, including issues related to FDA Form 483 and iLet’s safety. The complaint details allegations of undisclosed safety issues, inadequate remediation efforts, and a failure to investigate serious customer reports, leading to a significant stock price drop in January 2026.

Beta Bionics Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:ca7ed26ea094b:0-beta-bionics-q3-earnings-call-highlights/
Beta Bionics (BBNX) reported a 30% increase in Q3 net sales to $35.5 million, driven by new patient starts and pharmacy channel revenue, leading the company to raise the lower end of its full-year revenue outlook. A key highlight was the FDA clearance of its Mint patch pump, which is expected to launch commercially in Q1 2027 and aims to be the smallest automated insulin-delivery patch pump in the U.S. The company also detailed financial performance, operational expenses, cash position, and provided updated 2026 guidance, while also outlining plans for its 3D Intelligence algorithm resubmission and progress on Type 2 diabetes and bi-hormonal programs.
Advertisement

BETA BIONICS, INC. INVESTORS WITH LOSSES HAVE UNTIL NOVEMBER 3, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

https://www.globenewswire.com/news-release/2026/10/28/3390314/0/en/beta-bionics-inc-investors-with-losses-have-until-november-3-2026-to-join-securities-class-action-bernstein-liebhard-llp-announces-deadline.html
Bernstein Liebhard LLP is reminding investors of Beta Bionics, Inc. (NASDAQ: BBNX) that they have until November 3, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that Beta Bionics made materially false and misleading statements about its business operations and financial stability between June 30, 2025, and February 24, 2026, causing investors to suffer significant losses. Affected investors are encouraged to contact Bernstein Liebhard LLP to discuss their rights or to serve as lead plaintiff.

Beta Bionics, Inc. Stock 12‑Month Price Target Raised to $24.67, Implies 15% Upside

https://www.tradingview.com/news/tradingview:6e800514a21bc:0-beta-bionics-inc-stock-12-month-price-target-raised-to-24-67-implies-15-upside/
Beta Bionics, Inc. (BBNX) has seen its average 12-month price target increase from $24.24 to $24.67, according to estimates from 14 analysts, with forecasts ranging from $16 to $30.4 per share. This updated target suggests a 15% potential upside from the October 27 closing price. The consensus rating for BBNX remains a "Buy" among 15 analysts, with 11 "Buys" and 4 "Holds."

Beta Bionics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62641256/beta-bionics-q3-2026-earnings-call-transcript
Beta Bionics reported Q3 2026 net sales of $35.5 million, a 30% year-over-year growth, and received FDA clearance for Mint, a new patch pump set to launch in Q1 2027. The company raised $161 million to support Mint's commercialization and updated its full-year 2026 revenue guidance to $124-$126 million. They are also progressing with new algorithm developments and a pivotal trial for a fully closed-loop system, despite a temporary withdrawal and resubmission of their 3D Intelligence algorithm to the FDA.

Beta Bionics, Inc. (BBNX) Misses Q3 EPS by 20c

https://www.streetinsider.com/Earnings/Beta+Bionics%2C+Inc.+%28BBNX%29+Misses+Q3+EPS+by+20c/27241597.html
Beta Bionics, Inc. (NASDAQ: BBNX) reported a Q3 EPS of ($0.52), missing the analyst estimate of ($0.32) by $0.20. The company's revenue for the quarter was $35.5 million.

Bragar Eagel & Squire, P.C. Reminds Beta Bionics, Inc.

https://www.globenewswire.com/news-release/2026/10/27/3389528/0/en/bragar-eagel-squire-p-c-reminds-beta-bionics-inc-investors-they-have-until-november-3rd-to-seek-lead-plaintiff-role-with-the-firm.html
Bragar Eagel & Squire, P.C. reminds investors in Beta Bionics, Inc. that they have until November 3, 2026, to seek a lead plaintiff role in a class action lawsuit. The lawsuit alleges that Beta Bionics made false and misleading statements about its iLet Bionic Pancreas insulin pump, which purportedly malfunctioned and caused dangerous insulin dosing. Investors who purchased BBNX common stock between July 30, 2025, and February 24, 2026, and suffered losses are encouraged to contact the law firm.
Advertisement

BBNX Investor Class Action Filed: Beta Bionics Investors Are Alerted to the Upcoming November 3 Deadline in the Securities Fraud Class Action to Recover Losses

https://www.prnewswire.com/news-releases/bbnx-investor-class-action-filed-beta-bionics-investors-are-alerted-to-the-upcoming-november-3-deadline-in-the-securities-fraud-class-action-to-recover-losses-302920221.html
A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) and its executives for alleged securities fraud, following a significant stock drop. The lawsuit claims Beta Bionics misled investors about the safety and efficacy of its iLet medical device, which allegedly caused life-threatening hypoglycemia in users. Investors have until November 3, 2026, to seek appointment as lead plaintiff in the case.

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/beta-bionics-inc.-notice-of-november-3-2026-application-deadline-1242291
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) for investors who purchased common stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made false and misleading statements regarding its iLet Bionic Pancreas insulin pump, which is accused of malfunctioning and causing hypoglycemic events, and that the company failed to report thousands of related customer complaints to the FDA. Investors have until November 3, 2026, to apply to be a lead plaintiff.

BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

https://www.prnewswire.com/news-releases/bbnx-investor-deadline-beta-bionics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-302919365.html
Beta Bionics (BBNX) is facing a securities class action lawsuit for investors who purchased shares between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics concealed thousands of iLet safety complaints and failed to report them to the FDA, leading to a significant drop in stock price. Hagens Berman is investigating the claims and encouraging investors with substantial losses to join the class action.

What Should Beta Bionics, Inc. Investors Know After 37% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline

https://www.prnewswire.com/news-releases/what-should-beta-bionics-inc-investors-know-after-37-stock-drop-the-law-offices-of-frank-r-cruz-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302918388.html
The Law Offices of Frank R. Cruz announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) for investors who purchased securities between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made misleading statements and failed to disclose critical safety issues related to its iLet product, including over 18,000 complaints and numerous life-threatening hypoglycemic events that were not investigated or reported to the FDA. Investors who suffered losses and wish to participate as lead plaintiff must file a motion by November 3, 2026.

BBNX Investor Alert: Schall, Brown & Schwartz LLP Files

https://www.globenewswire.com/news-release/2026/10/26/3388215/0/en/bbnx-investor-alert-schall-brown-schwartz-llp-files-class-action-lawsuit-against-beta-bionics-inc-and-announces-opportunity-for-investors-to-lead-class-action-lawsuit.html
Schall, Brown & Schwartz LLP has filed a federal securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased common stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made false and misleading statements regarding its iLet Bionic Pancreas insulin pump, concealing serious issues with the device and the extent of FDA findings. Investors have until November 3, 2026, to seek appointment as lead plaintiff in the case.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement